Assessment of the quality of life indicators in patients with urate nephrolithiasis comorbid with metabolic syndrome

Authors

DOI:

https://doi.org/10.14739/2409-2932.2022.1.244446

Keywords:

urate nephrolithiasis, metabolic syndrome, quality of life

Abstract

Kidney stone disease (KSD) is one of the most common urological diseases; however, until recently, there was no specific tools for the study of the influence of urate nephrolithiasis (UN) on the patients’ quality of life. The use of WISQOL quality of life questionnaire enabled quantitative evaluation of the subjective notion and enhanced the insight on the condition of a patient with UN in general, for measuring the broad scope of functions of health perception.

The aim of the research is to study quality of life indicators in patients with UN comorbid with metabolic syndrome.

Materials and methods. The study included 65 patients with UN and UN comorbid with MS. In the control group, there were 21 patients with UN who received traditional therapy. The comparison group comprised 21 patients with UN comorbid with MS, who received both traditional therapy and drugs that correct metabolic disorders. The main group consisted of 23 patients with UN comorbid with MS, who took quertin against the background of the traditional therapy and drugs that correct metabolic disorders. To assess the quality of life, the WISQOL questionnaire was used, which included 4 domains: social impact (SI), emotional impact (EI), health impact (HI) and impact on life activity (ILA). The patients’ condition was assessed before treatment and after 1.5–6.0 months.

Results. After the treatment, main group patients demonstrated an increase of EI indicator; comparison group patients demonstrated an increase in EI, ILA, and HI indicators. The efficacy of quertin was confirmed by an increase in ILA, SI, and HI indicators.

Conclusions. The levels of SI and HI were decreasing before treatment in patients with UN comorbid with MS from the comparison and the main groups. The use of quertin against the background of the traditional therapy and drugs that correct metabolic processes, significantly increased EI and ILA levels.

Author Biography

S. I. Bilai, Zaporizhzhia State Medical University, Ukraine

PhD student of the Department of Urology

References

Amirdjanova, V. N., Goryachev, D. V., Korshunov, N. I., Rebrov, A. P., & Sorotskaya, V. N. (2008). Populyarnye pokazateli kachestva zhizni po oprosniku SF-36 (rezul'taty mnogotsentrovogo issledovaniya kachestva zhizni "Mirazh") [SF-36 questionnaire population quality of life indices Objective)]. Nauchno-prakticheskaya revmatologiya, 46(1), 36-48. [in Russian]. https://doi.org/10.14412/1995-4484-2008-852

Novik, A. A., & Ionova, T. I. (2002). Rukovodstvo po issledovaniyu kachestva zhizni v meditsine [Guidelines for Research on Quality of Life in Medicine]. OLMA-PRESS Zvezdnyi mir. [in Russian].

Heldwein, F. L., Sánchez-Salas, R. E., Sánchez-Salas, R., Teloken, P. E., Teloken, C., Castillo, O., & Vallancien, G. (2009). Health and quality of life in urology: issues in general urology and urological oncology. Archivos espanoles de urologia, 62(7), 519-530.

Protoshchak, V. V., Paronnikov, M. V., Babkin, P. A., & Kiselev, A. O. (2018). Kachestvo zhizni urologicheskikh bol'nykh [Quality of life of urological patients]. Urologiya, (5), 160-168. [in Russian]. https://doi.org.10.18565/urology.2018.5.160-168

Penniston, K. L., & Nakada, S. Y. (2013). Development of an instrument to assess the health related quality of life of kidney stone formers. The Journal of urology, 189(3), 921-930. https://doi.org/10.1016/j.juro.2012.08.247

Penniston, K. L., Antonelli, J. A., Viprakasit, D. P., Averch, T. D., Sivalingam, S., Sur, R. L., Pais, V. M., Jr, Chew, B. H., Bird, V. G., & Nakada, S. Y. (2017). Validation and Reliability of the Wisconsin Stone Quality of Life Questionnaire. The Journal of urology, 197(5), 1280-1288. https://doi.org/10.1016/j.juro.2016.11.097

Shalamai, A. S. (2012). Kvertsetin i Kvertin: bioflavonoidy na strazhe zdorov'ya [Quercetin and Quertin: Bioflavonoids on the Guardian of Health]. Kiev : Ferz'. [in Russian].

Maksyutina, N. P., Moibenko, A. A., Mokhort, N. A., Parkhomenko, A. N., Shalamai, A. S., Frantsuzova, S. B., Pilipchuk, L. B., Dosenko, V. E., Pashevin, D. A., Portnichenko, A. G., Nagibin, V. S., Pavlyuchenko, V. B., Kuz’menko, M. A., Kozhukhov, S. N., & Koval’, E. A. (2012). Bioflavonoidy kak organoprotektory: kvertsetin, korvitin, kvertin [Bioflavonoids as organoprotectors: Quercetin, Corvitin, Quertin]. Naukova dumka. [in Russian].

Penniston, K. L., & Nakada, S. Y. (2007). Health related quality of life differs between male and female stone formers. The Journal of urology, 178(6), 2435-2440. https://doi.org/10.1016/j.juro.2007.08.009

Shestaev, A. Y., Paronnikov, M. V., Protoshchak, V. V., Sinelnikov, L. M., Karpushchenko, E. G., & Kiselev, A. O. (2018). Russkoyazychnaya versiya Viskonsinskogo oprosnika dlya otsenki kachestva zhizni u patsientov s mochekamennoi bolezn'yu (Wisconsin stone QO WISQOL)): rezul'taty pilotnogo issledovaniya [Russian-language version of the Wisconsin questionnaire for assessing the quality of life in patients with urolithiasis (Wisconsin stone-QOL (WISQOL)): results of the pilot study]. Eksperimental'naya i klinicheskaya urologiya, 35(2), 50-56. [in Russian].

Published

2022-02-15

How to Cite

1.
Bilai SI. Assessment of the quality of life indicators in patients with urate nephrolithiasis comorbid with metabolic syndrome. Current issues in pharmacy and medicine: science and practice [Internet]. 2022Feb.15 [cited 2024Jul.21];15(1):67-71. Available from: http://pharmed.zsmu.edu.ua/article/view/244446

Issue

Section

Original research